SEC Charges uBiome Founders with Defrauding Investors

The microbiome-testing company made misleading claims about its prospects and about its business strategy, which allegedly relied on fooling doctors into ordering unnecessary tests, according to the US government.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, EVGEN_PROZHYRKO

The founders of uBiome, a microbiome-testing company that went bankrupt and shut down after being raided by the Federal Bureau of Investigation in 2019, were charged with securities fraud by the Securities and Exchange Commission on Thursday (March 18). Jessica Richman and Zachary Apte are accused of defrauding investors out of $60 million by making false claims about the company’s prospects and by allegedly covering up a scheme that involved persuading doctors to order unnecessary tests from the company and claiming reimbursement from insurers.

“We allege that Richman and Apte touted uBiome as a successful and fast-growing biotech pioneer while hiding the fact that the company’s purported success depended on deceit,” Erin Schneider, the director of the Securities and Exchange Commission (SEC) San Francisco Regional Office, says in a statement. “Investors are entitled to know the material risks of the companies they are investing in, no ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Catherine Offord

    Catherine is a science journalist based in Barcelona.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Conceptual 3D image of DNA on a blue background.

Understanding the Nuts and Bolts of qPCR Assay Controls 

Bio-Rad
Takara Bio

Takara Bio USA Holdings, Inc. announces the acquisition of Curio Bioscience, adding spatial biology to its broad portfolio of single-cell omics solutions

Sapio Sciences

Sapio Sciences Announces Enhanced Capabilities for Chemistry, Immunogenicity, GMP and Molecular Biology

Biotium Logo

Biotium Unveils the Most Sensitive Stains for DNA or RNA with New EMBER™ Ultra Agarose Gel Kits